Compare Stocks: BHVN, ALKS, IOVA, and GRAL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$41.22 +2.8%	$45.02	$27.00 ▼ $55.67	$6.73B	0.32	2.59 million shs	3.41 million shs
BHVN Biohaven	$10.83 -5.3%	$13.70	$7.48 ▼ $18.57	$1.73B	1.35	2.30 million shs	2.42 million shs
GRAL GRAIL	$117.81 -13.0%	$98.79	$41.50 ▼ $166.48	$6.05B	2.83	1.50 million shs	1.30 million shs
IOVA Iovance Biotherapeutics	$13.62 -7.5%	$10.17	$1.76 ▼ $15.30	$6.67B	0.76	18.02 million shs	12.16 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+2.79%	+1.50%	-10.53%	-21.81%	+27.89%
BHVN Biohaven	-5.38%	-10.57%	-10.04%	-29.95%	-37.81%
GRAL GRAIL	-13.03%	-16.20%	+56.85%	+62.23%	+56.00%
IOVA Iovance Biotherapeutics	-7.47%	-6.84%	+37.99%	+172.40%	+508.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$41.22 +2.8%	$45.02	$27.00 ▼ $55.67	$6.73B	0.32	2.59 million shs	3.41 million shs
BHVN Biohaven	$10.83 -5.3%	$13.70	$7.48 ▼ $18.57	$1.73B	1.35	2.30 million shs	2.42 million shs
GRAL GRAIL	$117.81 -13.0%	$98.79	$41.50 ▼ $166.48	$6.05B	2.83	1.50 million shs	1.30 million shs
IOVA Iovance Biotherapeutics	$13.62 -7.5%	$10.17	$1.76 ▼ $15.30	$6.67B	0.76	18.02 million shs	12.16 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+2.79%	+1.50%	-10.53%	-21.81%	+27.89%
BHVN Biohaven	-5.38%	-10.57%	-10.04%	-29.95%	-37.81%
GRAL GRAIL	-13.03%	-16.20%	+56.85%	+62.23%	+56.00%
IOVA Iovance Biotherapeutics	-7.47%	-6.84%	+37.99%	+172.40%	+508.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.68	Moderate Buy	$54.47	32.15% Upside
BHVN Biohaven	2.59	Moderate Buy	$18.69	72.63% Upside
GRAL GRAIL	2.33	Hold	$119.80	1.69% Upside
IOVA Iovance Biotherapeutics	2.62	Moderate Buy	$13.20	-3.08% Downside

Current Analyst Ratings Breakdown

Latest BHVN, ALKS, IOVA, and GRAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	ALKS Alkermes	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
10/15/2026	GRAL GRAIL	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/13/2026	GRAL GRAIL	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$88.00 ➝ $180.00
10/12/2026	GRAL GRAIL	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$60.00 ➝ $120.00
10/8/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$6.00 ➝ $11.00
10/2/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $175.00
10/1/2026	GRAL GRAIL	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$75.00 ➝ $155.00
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.69	$1.72 per share	23.95	$11.02 per share	3.74
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
GRAL GRAIL	$147.17M	35.76	N/A	N/A	$66.13 per share	1.78
IOVA Iovance Biotherapeutics	$263.50M	23.41	N/A	N/A	$1.76 per share	7.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	108.48	171.75	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)

Latest BHVN, ALKS, IOVA, and GRAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	GRAL GRAIL	-$2.5017	N/A	N/A	N/A	$44.21 million	N/A
11/9/2026	Q3 2026	BHVN Biohaven	-$0.6097	N/A	N/A	N/A	$70.00 million	N/A
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0847	N/A	N/A	N/A	$115.53 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0809	N/A	N/A	N/A	$463.35 million	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
BHVN Biohaven	21.23	4.73	4.73
GRAL GRAIL	N/A	10.95	10.95
IOVA Iovance Biotherapeutics	N/A	4.34	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
BHVN Biohaven	88.78%
GRAL GRAIL	N/A
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
BHVN Biohaven	13.80%
GRAL GRAIL	1.83%
IOVA Iovance Biotherapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable

BHVN, ALKS, IOVA, and GRAL Headlines

Recent News About These Companies

Barclays lifts target for Iovance Biotherapeutics stock to USD 18.00

October 16 at 5:29 PM | ad-hoc-news.deA

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 16 at 5:15 PM | globenewswire.com

Iovance Halts Pediatric TIL Trial, Nudging Investor Focus Back to Core Programs

October 16 at 12:30 PM | tipranks.com

Jefferies Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

October 15 at 3:14 PM | theglobeandmail.com

Iovance Biotherapeutics, Inc. (IOVA) - What Are Investment Firms Saying About This Stock?

October 14 at 2:15 AM | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Has Average Price Target of $13.20

October 14 at 2:13 AM | marketbeat.com

30 U.S. stocks flashing Strong Buy ratings as earnings roll in

October 14 at 1:16 AM | seekingalpha.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Climb 6.6% After Analyst Upgrade

October 11, 2026 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Expected to Rise, Robert W. Baird Analyst Says

October 10, 2026 | americanbankingnews.com

Iovance Expands Lifileucel Into Sarcoma: What SARATOGA Means for Investors

October 9, 2026 | tipranks.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.6% on Analyst Upgrade

October 9, 2026 | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Gets Price Target Increase from Robert W. Baird

October 8, 2026 | marketbeat.com

AVBCC Recognizes Iovance Biotherapeutics’ Dr. Fred Vogt with Inaugural Global Cancer Research & Innovation Award

October 7, 2026 | greenbaypressgazette.comG

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.2% - Here's Why

October 6, 2026 | marketbeat.com

Iovance: Buy Now Before Many Growth Catalysts Kick In

October 5, 2026 | seekingalpha.com

Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3

October 4, 2026 | finance.yahoo.com

Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook

October 3, 2026 | finance.yahoo.com

Why Is Iovance Biotherapeutics (NASDAQ:IOVA) Suddenly a Must-Watch Healthcare Stocks Name?

October 2, 2026 | kalkinemedia.comK

Iovance Biotherapeutics consensus price target increased by 34.74% to $13.06

October 2, 2026 | msn.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

October 2, 2026 | zacks.com

What is Zacks Research's Forecast for IOVA FY2026 Earnings?

October 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BHVN, ALKS, IOVA, and GRAL Company Descriptions

Alkermes NASDAQ:ALKS

$41.22 +1.12 (+2.79%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$41.16 -0.06 (-0.15%)

As of 10/16/2026 07:53 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Biohaven NYSE:BHVN

$10.82 -0.61 (-5.29%)

Closing price 10/16/2026 03:59 PM Eastern

Extended Trading

$11.04 +0.22 (+2.03%)

As of 10/16/2026 07:30 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

GRAIL NASDAQ:GRAL

$117.81 -17.65 (-13.03%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$118.50 +0.69 (+0.59%)

As of 10/16/2026 07:57 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Iovance Biotherapeutics NASDAQ:IOVA

$13.62 -1.10 (-7.47%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$13.60 -0.02 (-0.18%)

As of 10/16/2026 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, ALKS, IOVA, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, ALKS, IOVA, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, ALKS, IOVA, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BHVN, ALKS, IOVA, and GRAL Company Descriptions

Alkermes NASDAQ:ALKS

Biohaven NYSE:BHVN

GRAIL NASDAQ:GRAL

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, ALKS, IOVA, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, ALKS, IOVA, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, ALKS, IOVA, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BHVN, ALKS, IOVA, and GRAL Company Descriptions

Alkermes NASDAQ:ALKS

Biohaven NYSE:BHVN

GRAIL NASDAQ:GRAL

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools